← Leaderboards
Jindan Yu
University Of Michigan At Ann Arbor
$10,147,010
Attributed
$12,100,267
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2008–25$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,100,267 · 10
By mechanism
R01$9,651,284 · 6
P50$1,401,575 · 1
R00$732,062 · 1
K99$310,346 · 1
R13$5,000 · 1
Top collaborators
- Changsheng Zhao5 shared
- Gary E Schiltz2 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Weiping Zou$38,970,401
- Kathleen A Cooney$10,810,865
- Celina G Kleer$13,464,529
- Marina Pasca Di Magliano$14,782,555
- Jacques Eduardo Nor$18,171,241
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsGenesMalignant Neoplasm Of ProstateMetastatic Prostate CancerCancer EtiologyCessation Of LifeNeoplasm MetastasisIn VivoIn VitroAmericanProteinsMediatingGene ExpressionDiagnosisMalignant NeoplasmsProstate Cancer CellTumorOperative Surgical ProceduresCellsGrowthRegulationPlayAndrogen ReceptorMolecular
Grant awards (35)
Development of Protein Degraders Targeting EZH2 Non-enzymatic Functions in Prostate Cancer$643,148
R01 · FY2025 · CA · contact PI
Molecular Mechanisms Underlying Luminal- Neuroendocrine Transdifferentiation$541,236
R01 · FY2025 · CA
FOXA1 regulates cytokine signaling and immune landscape in prostate cancer through ARID1A$513,659
R01 · FY2025 · CA · contact PI
Comprehensive Analyses of HOXB13-regulated Transcriptional programs critical for Prostate Cancer Progression$477,455
R01 · FY2025 · CA · contact PI
Development of Protein Degraders Targeting EZH2 Non-enzymatic Functions in Prostate Cancer$663,713
R01 · FY2024 · CA · contact PI
Molecular Mechanisms Underlying Luminal- Neuroendocrine Transdifferentiation$541,236
R01 · FY2024 · CA
FOXA1 regulates cytokine signaling and immune landscape in prostate cancer through ARID1A$490,082
R01 · FY2024 · CA · contact PI
Comprehensive Analyses of HOXB13-regulated Transcriptional programs critical for Prostate Cancer Progression$453,582
R01 · FY2024 · CA · contact PI
FOXA1 regulates cytokine signaling and immune landscape in prostate cancer through ARID1A$513,441
R01 · FY2023 · CA · contact PI
Comprehensive Analyses of HOXB13-regulated Transcriptional programs critical for Prostate Cancer Progression$467,905
R01 · FY2023 · CA · contact PI
Comprehensive analyses of HOXB13-regulated transcriptional programs critical for prostate cancer progression$478,370
R01 · FY2022 · CA · contact PI
Role of NF90 in Prostate Cancer$286,708
R01 · FY2022 · CA · contact PI
Role of NF90 in Prostate Cancer$67,489
R01 · FY2022 · CA · contact PI
Society for Basic Urologic Research 2021 Annual Meeting: Molecular Mechanisms of Urological Diseases and Treatment Resistance$5,000
R13 · FY2022 · CA · contact PI
Comprehensive analyses of HOXB13-regulated transcriptional programs critical for prostate cancer progression$485,082
R01 · FY2021 · CA · contact PI
Role of NF90 in Prostate Cancer$361,425
R01 · FY2021 · CA · contact PI
Role of NF90 in Prostate Cancer$361,425
R01 · FY2020 · CA · contact PI
Role of NF90 in Prostate Cancer$350,581
R01 · FY2019 · CA · contact PI
Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancer$273,910
P50 · FY2019 · CA · contact PI
Role of NF90 in Prostate Cancer$361,425
R01 · FY2018 · CA · contact PI
Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancer$291,574
P50 · FY2018 · CA · contact PI
The Role of NOV (CCN3) in Prostate Cancer Progression$320,588
R01 · FY2017 · CA · contact PI
Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancer$293,764
P50 · FY2017 · CA · contact PI
The Role of NOV (CCN3) in Prostate Cancer Progression$320,588
R01 · FY2016 · CA · contact PI
Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancer$261,640
P50 · FY2016 · CA · contact PI
The Role of NOV (CCN3) in Prostate Cancer Progression$320,588
R01 · FY2015 · CA · contact PI
Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancer$280,687
P50 · FY2015 · CA · contact PI
The Role of NOV (CCN3) in Prostate Cancer Progression$310,970
R01 · FY2014 · CA · contact PI
The Role of NOV (CCN3) in Prostate Cancer Progression$320,588
R01 · FY2013 · CA · contact PI
The Role of beta-adrenergic Signaling in Prostate Cancer$241,531
R00 · FY2012 · CA · contact PI
The Role of beta-adrenergic Signaling in Prostate Cancer$241,531
R00 · FY2011 · CA · contact PI
The Role of beta-adrenergic Signaling in Prostate Cancer$249,000
R00 · FY2010 · CA · contact PI
The Role of beta-adrenergic Signaling in Prostate Cancer$130,014
K99 · FY2009 · CA · contact PI
The Role of beta-adrenergic Signaling in Prostate Cancer$53,162
K99 · FY2009 · CA · contact PI
The Role of beta-adrenergic Signaling in Prostate Cancer$127,170
K99 · FY2008 · CA · contact PI